Where this brief could be wrong
From the latest edition of each brief.
Biotech & Pharma Intelligence
Our biggest conclusion, the strongest case against it, and what would settle it.
RED TEAM
Base case. Pan-RAS drugs are moving toward first-line pancreatic cancer, on single-arm data. Analysis
Counter-case. Response rates in small, selected groups often shrink in randomized trials, and adding a drug that also blocks normal RAS to chemotherapy may cost tolerability that a short single-arm study does not show.
What would settle it. RASolute 303’s survival comparison against chemotherapy alone, and full safety tables for both drugs.
| Consensus | Counter-case | What would settle it |
|---|---|---|
| Xanamem may still work in older patients | The subgroup came after a missed primary, and its mean slowing was not significant | A new trial in older patients with that as its primary |
| Sanofi may bid for Insmed | The report cites unnamed sources and no price; companies weigh many deals they never make | An announcement by either company |
BLIND SPOT CHECK
GlobeNewswire’s search and the Business Wire newsroom did not load, so wire coverage was partial. We read Revolution’s release through Investing News, Alnylam’s through Yahoo Finance and Actinogen’s through BioSpace, and read DISCO’s release through Yahoo Finance. The Insmed report is secondhand, the CME FedWatch reading comes through a newsletter, and the Insmed report has no public primary copy. ClinicalTrials.gov, Open Targets, ChEMBL and PubMed were reached through their connectors. Early European and Asian releases may be missing.
AI & Technology Intelligence
| Consensus | Counter-case | What would settle it |
|---|---|---|
| The sell-off is about AI spending | It may be mostly forced selling around expiry | Trading in the week of 11.23 |
| Anthropic’s IPO pulled money from other tech | No flow data shows it, and ANT fell too | Weekly fund-flow data |
| China rules are hitting chipmakers | The claims are not findings | Commerce license decisions |
| The cloud buyers will keep spending | Budgets can be cut at the next results | Late-January guidance |
BLIND SPOT CHECK
We did not open Bloomberg, CNBC, Reuters’ full stories, the Hunterbrook report itself or the Federal Register page directly. Stock prices are last regular-session trades. We did not re-run Source watch or the capital tally. Analysis
Life Intelligence
RED TEAM
Base case. Door 7 calls it Mixed: colds come from viruses, but a 2005 trial found more reported colds after a foot chill.
Counter-case. That rests on one trial of 180 adults, self-reported colds, no infection test and a P value just under the usual cutoff. Earlier clinical research hadn’t shown an effect. If the trial was a fluke, “not supported” is the fairer verdict.
What would settle it. A larger trial that tests for infection, not just symptoms. We haven’t seen one.
Also. Door 5’s travel line rests on the UK view; the U.S. State Department’s Senegal page still shows an advisory issued February 20, 2019, so we print no U.S. level. Check it before you book. Door 1’s tracks have Bandcamp players, but nobody has confirmed in a browser that they play free.


